Sabai Global/Clinical Biosafety Services
Garry Coulson, PhD, MS, RBP currently serves as Director, Regulatory at Sabai Global and also serves as an Institutional Biosafety Committee (IBC) Chair with Clinical Biosafety Services (CBS) responsible for reviewing human gene transfer or gene therapy clinical trials subject to the NIH Guidelines. In this capacity, Garry has chaired the review of 500+ clinical trials at over 200 institutions nationwide. Prior to joining Sabai Global and CBS, he was in research administration at the University of North Carolina at Chapel Hill where he managed the Biological Safety Division and operations relating to the IBC review of human gene transfer (HGT) clinical trials and basic research protocols. Preceding that, he was actively engaged in basic and translational research in academic, industry and government sectors with primary research interests focused on infectious diseases, epidemiology, immunology, and drug discovery. He holds a PhD in Infectious Diseases and a Master’s in Clinical Microbiology, and is a Registered Biosafety Professional with ABSA International.
F16 - [IN-PERSON/RECORDED] Mission Overlap Between IRBs and IBCs and the Institutional Implications
Wednesday, December 6, 2023
10:15 AM – 11:15 AM ET